YUTOPAR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for YUTOPAR (YUTOPAR).
Selective beta-2 adrenergic receptor agonist; relaxes uterine smooth muscle by increasing intracellular cAMP, reducing myosin light chain kinase activity and inhibiting uterine contractions.
| Metabolism | Primarily hepatic via conjugation (glucuronidation and sulfation) and CYP450 isoenzymes (CYP3A4, CYP2D6). |
| Excretion | Primarily renal (90-95% as unchanged drug and metabolites); less than 5% fecal. |
| Half-life | 1.7-2.5 hours (terminal); increased in renal impairment. |
| Protein binding | 25-30% (primarily albumin). |
| Volume of Distribution | 0.3-0.5 L/kg; distributes mainly into extracellular fluid. |
| Bioavailability | Not applicable (only IV route used clinically). |
| Onset of Action | Intravenous: 5-10 minutes. |
| Duration of Action | 1-3 hours; dose-dependent; uterus may remain refractory to oxytocin for up to 30 min after infusion stop. |
| Action Class | Beta 2 agonist - Uterus |
| Brand Substitutes | Isoxsprin 10mg Tablet, Unisox 10mg Tablet, Isox 10mg Tablet, Fetocare 10mg Tablet, Ecorit 10mg Tablet, Utgard 50mg Injection, Ritodine 50mg Injection, Ritrod 50mg Injection |
Initial dose of 50 mcg/min IV, increased by 50 mcg/min every 10-20 minutes until uterine contractions cease or maximum of 350 mcg/min is reached. Maintenance at the lowest effective dose for 12-24 hours after contractions stop.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment is recommended; however, use with caution in patients with renal impairment as drug elimination may be reduced. |
| Liver impairment | No specific dose adjustment is recommended; however, use with caution in patients with hepatic impairment due to potential for altered metabolism. |
| Pediatric use | Not indicated for pediatric use; safety and efficacy in children have not been established. |
| Geriatric use | Not indicated for use in elderly patients; specifically used for preterm labor in pregnant women. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for YUTOPAR (YUTOPAR).
| Breastfeeding | Excreted in breast milk; concentration likely low. M/P ratio not reported. Caution advised; consider risk-benefit. |
| Teratogenic Risk | FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. In humans, limited data; use only if clearly needed. Risk of maternal pulmonary edema and fetal tachycardia at high doses; monitor fetal heart rate. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to ritodrine or any component.","Maternal cardiac disease (e.g., tachyarrhythmias, myocardial insufficiency, severe hypertension).","Preeclampsia/eclampsia.","Intrauterine infection (chorioamnionitis).","Fetal distress or death.","Placental abruption or hemorrhage.","Cervical dilation > 4 cm or rupture of membranes."]
| Precautions | ["Maternal pulmonary edema, especially with multiple gestation or concurrent corticosteroids.","Maternal cardiac effects: tachycardia, myocardial ischemia, arrhythmias.","Fetal effects: tachycardia, hypoglycemia, hypocalcemia, ileus.","Hypokalemia due to beta-2 stimulation.","Paradoxical bronchospasm in asthmatics."] |
Loading safety data…
| Monitor maternal heart rate, blood pressure, respiratory rate, serum potassium, and glucose. Fetal heart rate monitoring. Assess for signs of pulmonary edema (dyspnea, crackles). |
| Fertility Effects | No known adverse effects on fertility. Not indicated for use in non-pregnant women. |